Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Apr;39(4):953–957. doi: 10.1128/aac.39.4.953

Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis.

M de Górgolas 1, P Avilés 1, C Verdejo 1, M L Fernández Guerrero 1
PMCID: PMC162660  PMID: 7786002

Abstract

Using two strains of Staphylococcus aureus, one susceptible and one heterogeneously resistant to methicillin, for which MICs and MBCs of trimethoprim-sulfamethoxazole (TMP-SMX) were 0.06 and 0.06 micrograms/ml and 0.06 and 0.25 microgram/ml, respectively (concentrations are those of TMP), we studied the efficacies of TMP-SMX and cloxacillin, teicoplanin, and vancomycin for treatment of experimental staphylococcal endocarditis. Rabbits were treated with dosages of TMP-SMX selected to achieve concentrations in serum equivalent to that obtained in humans treated for Pneumocystis carinii pneumonia. The overall mortality rate of rabbits treated with TMP-SMX was 84% at day 3, not different from that of the control groups (P > 0.1). No sterile vegetations were observed to be present in control groups or in animals treated with TMP-SMX. However, 26, 60, and 75% of rabbits treated with teicoplanin, cloxacillin, and vancomycin, respectively, showed sterile vegetations. For methicillin-susceptible S. aureus (MSSA), the mean vegetation counts were not significantly different between the control group and the group treated with TMP-SMX (P > 0.1). For methicillin-resistant S. aureus (MRSA), treatment with TMP-SMX was more effective than no therapy, decreasing the number of organisms in vegetations (P < 0.01). For both strains, therapy with cloxacillin and therapy with teicoplanin or vancomycin were significantly more effective than therapy with TMP-SMX. Despite high concentrations of teicoplanin in serum which exceeded MBCs for staphylococci more than 50 times at the peak and 10 times at the trough, therapy with cloxacillin or vancomycin was superior to therapy with teicoplanin against both MSSA and MRSA. These data do not support the use of TMP-SMX in treatment of endocarditis and other severe staphylococcal infections with high bacterial counts.

Full Text

The Full Text of this article is available as a PDF (189.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bengtsson E., Svanbom M., Tunevall G. Trimethoprim-sulphamethoxazole treatment in staphylococcal endocarditis and gram-negative septicemia. Scand J Infect Dis. 1974;6(2):177–182. doi: 10.3109/inf.1974.6.issue-2.13. [DOI] [PubMed] [Google Scholar]
  2. Boyce J. M. Increasing prevalence of methicillin-resistant Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol. 1990 Dec;11(12):639–642. doi: 10.1086/646114. [DOI] [PubMed] [Google Scholar]
  3. Bushby S. R., Hitchings G. H. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol Chemother. 1968 May;33(1):72–90. doi: 10.1111/j.1476-5381.1968.tb00475.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chambers H. F., Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother. 1990 Apr;34(4):510–514. doi: 10.1128/aac.34.4.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chambers H. F., Sande M. A. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Jul;26(1):61–64. doi: 10.1128/aac.26.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chambers H. F. Short-course combination and oral therapies of Staphylococcus aureus endocarditis. Infect Dis Clin North Am. 1993 Mar;7(1):69–80. [PubMed] [Google Scholar]
  7. Cremieux A. C., Maziere B., Vallois J. M., Ottaviani M., Azancot A., Raffoul H., Bouvet A., Pocidalo J. J., Carbon C. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis. 1989 May;159(5):938–944. doi: 10.1093/infdis/159.5.938. [DOI] [PubMed] [Google Scholar]
  8. Elwell L. P., Wilson H. R., Knick V. B., Keith B. R. In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Jun;29(6):1092–1094. doi: 10.1128/aac.29.6.1092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Freedman L. R., Arnold S., Valone J. Experimental endocarditis. Ann N Y Acad Sci. 1974 Jul 31;236(0):456–465. doi: 10.1111/j.1749-6632.1974.tb41510.x. [DOI] [PubMed] [Google Scholar]
  10. Grose W. E., Bodey G. P., Loo T. L. Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 1979 Mar;15(3):447–451. doi: 10.1128/aac.15.3.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hackbarth C. J., Chambers H. F. Methicillin-resistant staphylococci: detection methods and treatment of infections. Antimicrob Agents Chemother. 1989 Jul;33(7):995–999. doi: 10.1128/aac.33.7.995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hartstein A. I., Mulligan M. E., Morthland V. H., Kwok R. Y. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol. 1992 Mar;30(3):670–674. doi: 10.1128/jcm.30.3.670-674.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hessen M. T., Pitsakis P. G., Levison M. E. Absence of a postantibiotic effect in experimental Pseudomonas endocarditis treated with imipenem, with or without gentamicin. J Infect Dis. 1988 Sep;158(3):542–548. doi: 10.1093/infdis/158.3.542. [DOI] [PubMed] [Google Scholar]
  14. Lawrence T., Rotstein C., Beam T. R., Jr, Gorzynski E. A., Amsterdam D. In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci. Antimicrob Agents Chemother. 1993 Apr;37(4):896–900. doi: 10.1128/aac.37.4.896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Maple P. A., Hamilton-Miller J. M., Brumfitt W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet. 1989 Mar 11;1(8637):537–540. doi: 10.1016/s0140-6736(89)90076-7. [DOI] [PubMed] [Google Scholar]
  16. Markowitz N., Quinn E. L., Saravolatz L. D. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992 Sep 1;117(5):390–398. doi: 10.7326/0003-4819-117-5-390. [DOI] [PubMed] [Google Scholar]
  17. Mortara L. A., Bayer A. S. Staphylococcus aureus bacteremia and endocarditis. New diagnostic and therapeutic concepts. Infect Dis Clin North Am. 1993 Mar;7(1):53–68. [PubMed] [Google Scholar]
  18. Patel R. B., Welling P. G. Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole). Clin Pharmacokinet. 1980 Sep-Oct;5(5):405–423. doi: 10.2165/00003088-198005050-00001. [DOI] [PubMed] [Google Scholar]
  19. Perlman B. B., Freedman L. R. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J Biol Med. 1971 Oct;44(2):206–213. [PMC free article] [PubMed] [Google Scholar]
  20. Sanabria T. J., Alpert J. S., Goldberg R., Pape L. A., Cheeseman S. H. Increasing frequency of staphylococcal infective endocarditis. Experience at a university hospital, 1981 through 1988. Arch Intern Med. 1990 Jun;150(6):1305–1309. [PubMed] [Google Scholar]
  21. Scheld W. M., Keeley J. M., Field M. R., Brodeur J. P. Co-trimoxazole versus nafcillin in the therapy of experimental meningitis due to Staphylococcus aureus. J Antimicrob Chemother. 1987 May;19(5):647–658. doi: 10.1093/jac/19.5.647. [DOI] [PubMed] [Google Scholar]
  22. Shafqat S. H., Shah S. A., Seyed S. A. Bacterial endocarditis over prosthetic valves treated with trimethoprim-sulphamethoxazole combination. Br Heart J. 1971 Nov;33(6):974–976. doi: 10.1136/hrt.33.6.974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Street A. C., Durack D. T. Experience with trimethoprim-sulfamethoxazole in treatment of infective endocarditis. Rev Infect Dis. 1988 Sep-Oct;10(5):915–921. doi: 10.1093/clinids/10.5.915. [DOI] [PubMed] [Google Scholar]
  24. Tamer M. A., Bray J. D. Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis. Clin Pediatr (Phila) 1982 Feb;21(2):125–126. doi: 10.1177/000992288202100211. [DOI] [PubMed] [Google Scholar]
  25. Verdejo C., Fernández Guerrero M. L., Castrillo J. M., Fernández Clúa M. A., Díaz Curiel M., de Villalobos E. Endocarditis por Staphylococcus aureus en adictos y no adictos: un mismo microbio para dos enfermedades distintas. Rev Clin Esp. 1989 Jul-Aug;185(3):123–127. [PubMed] [Google Scholar]
  26. Winston D. J., Lau W. K., Gale R. P., Young L. S. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1980 Jun;92(6):762–769. doi: 10.7326/0003-4819-92-6-762. [DOI] [PubMed] [Google Scholar]
  27. Yeldandi V., Strodtman R., Lentino J. R. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother. 1988 Dec;22(6):873–880. doi: 10.1093/jac/22.6.873. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES